Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cannabinoid receptor 2 (macrophage) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.1868 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1868 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.1868 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1868 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.1868 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.1868 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.1868 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.1868 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.1868 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.1868 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.1153 | 0.2407 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.1868 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1655 | 0.7743 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.1868 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.1868 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1868 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.1868 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0941 | 0.0151 | 0.0151 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.1655 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0927 | 0 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.1868 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.1153 | 0.2407 | 0.2407 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.1868 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.1868 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1868 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.1868 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0927 | 0 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.1868 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.1868 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 22 nM | Agonist activity at human CB2 receptor assessed as inhibition of forskolin-stimulated cAMP production | ChEMBL. | 18440813 |
Emax (functional) | = 28 % | Agonist activity at human CB2 receptor assessed as inhibition of forskolin-stimulated cAMP production relative to 2-arachidonoylglycerol | ChEMBL. | 18440813 |
Ki (binding) | Displacement of [3H]SR141716A from human CB1 receptor | ChEMBL. | 18440813 | |
Ki (binding) | = 41 nM | Displacement of [3H]CP-55940 from human CB2 receptor | ChEMBL. | 18440813 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.